Why the study?
How genomic instability influences the metabolic capacity of cancer cells is poorly understood.
Population
Breast and ovarian cancer homologous recombination-defective models and patient-derived xenografts
Design
Preclinical laboratory study
Authors
Loading...
Hypothesis-generating for OXPHOS inhibition to enhance PARPi efficacy in HRD cancers; human trials required before clinical consideration.
Homologous recombination-defective cancers rely on oxidative phosphorylation, suggesting a novel therapeutic vulnerability to OXPHOS inhibitors like metformin and a mechanism for PARP inhibitor resistance.
Lahiguera et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: